HomeAI · summaries
Storia in 5 fonti
Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa
Viridian Therapeutics has scored an FDA
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5…
- ·
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators recommending that the ANCA-associated vasculitis…
- ·
morningstar.com
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
- ·
endpoints.news
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion burden.
- ·
Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa
Viridian Therapeutics has scored an FDA
- ·
benzinga.com
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.
- ·
biopharmadive.com
Viridian may have edge over Amgen in eye drug showdown, analysts argue
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease…
- ·
Unicycive turned away by FDA again over manufacturer’s plant shortfalls
After Unicycive Therapeutics had its drug application for oxylanthanum carbonate (OLC)
- ·
FDA selects Lilly, Regeneron, Fujifilm, 4 others for PreCheck Pilot Program
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares are among the seven companies